Clinical Trials

Numerous clinical trials evaluate maraviroc across Phase 1 through Phase 4, focusing on HIV-1 infections, comorbidities like renal disease and viral co-infections, acute ischemic stroke, post-stroke cognitive impairment, and SARS-CoV-2. Featuring recruiting, completed, and terminated statuses, these studies are sponsored by academic institutions, government entities such as the National Institute of Allergy and Infectious Diseases, and pharmaceutical leaders including ViiV Healthcare and GlaxoSmithKline.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07668505 NOT_YET_RECRUITING
Myositis
Chinese University of Hong Kong
 2026-09-01 PHASE4
NCT06853223 RECRUITING
Primary Graft Dysfunction; Lung Transplantation; Acute Lung Injury(ALI); Natural Killer Cell Mediated Immunity
University of California, San Francisco
 2025-12-07 PHASE2
NCT07080567 RECRUITING
Ischemic Stroke; Stroke; Stroke Acute
Emmanuel Carrera
 2025-07-14 PHASE2
NCT05470491 RECRUITING
HIV; Hematologic Malignancies
National Cancer Institute (NCI)
 2023-01-26 PHASE1; PHASE2
NCT06805656 RECRUITING
Hiv; HIV I Infection
Federal University of São Paulo
 2026-07-15 PHASE2
NCT06974084 NOT_YET_RECRUITING
Long COVID
HealthBio, Inc.
 2026-07-15 PHASE2; PHASE3
NCT04789616 UNKNOWN
Stroke
University of Calgary
 2022-09-15 PHASE2
NCT03118661 WITHDRAWN
HIV-1-infection
Washington University School of Medicine
 2018-03-19 PHASE1
NCT04966429 UNKNOWN
Post Stroke Cognitive Impairment
Tel-Aviv Sourasky Medical Center
 2021-05-01 PHASE2
NCT04721301 COMPLETED
Colorectal Cancer Metastatic; Pancreatic Cancer Metastatic
University Hospital Heidelberg
 2017-01-15 PHASE1
NCT05932550 COMPLETED
Post-stroke Depression
Tel-Aviv Sourasky Medical Center
 2020-08-04 PHASE2
NCT02741323 COMPLETED
HIV Infections; Kidney Diseases
National Institute of Allergy and Infectious Diseases (NIAID)
 2017-01-01 PHASE2
NCT04475991 TERMINATED
COVID-19
Hospital General de México Dr. Eduardo Liceaga
 2021-07-13 PHASE2
NCT04710199 COMPLETED
Virus Diseases
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
 2021-02-23 PHASE2
NCT04966429 Recruiting
Post Stroke Cognitive Impairment
Tel-Aviv Sourasky Medical Center|Hadassah Medical Organization|Soroka University Medical Center
 2021-05-01 Phase 2
NCT04965662 COMPLETED
HIV-1-infection
Guy's and St Thomas' NHS Foundation Trust
 2018-01-01 PHASE4
NCT04441385 TERMINATED
COVID-19
Hospital Universitario Infanta Leonor
 2020-06-26 PHASE2
NCT04710199 Completed
Virus Diseases
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
 2021-02-23 Phase 2
NCT04435522 COMPLETED
COVID
Rhode Island Hospital
 2020-10-01 PHASE1
NCT03129113 COMPLETED
Hepatic Steatosis; HIV-1-infection
University College, London
 2017-03-01 PHASE2; PHASE3
NCT03172026 TERMINATED
Stroke
University of California, Los Angeles
 2019-08-01 PHASE2; PHASE3
NCT03163277 TERMINATED
Hiv; Neurocognitive Dysfunction
Giovanni Di Perri
 2017-05-15 PHASE4
NCT03274804 COMPLETED
Metastatic Colorectal Cancer; MSS
University Hospital Heidelberg
 2018-04-01 PHASE1
NCT02519777 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2016-04-21 PHASE4
NCT02778204 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2017-06-05 PHASE1
NCT02990312 WITHDRAWN
Hiv; Kidney Transplant; HIV Reservoir; CCR5
University of Maryland, Baltimore
 2017-05-01 PHASE4
NCT02881762 COMPLETED
Hepatitis C; Human Immunodeficiency Virus
University of Maryland, Baltimore
 2017-06-01 PHASE4
NCT02961829 COMPLETED
Chronic Infection; HIV
Federal University of São Paulo
 2015-07
NCT02159027 COMPLETED
AIDS Dementia Complex
University of Hawaii
 2015-06 PHASE2; PHASE3
NCT03218592 COMPLETED
HIV/AIDS
University of North Carolina, Chapel Hill
 2017-06-28 PHASE4
NCT01896921 COMPLETED
HIV
University of Maryland, Baltimore
 2013-09 PHASE3
NCT02167451 TERMINATED
Diagnoses That Require Stem Cell Transplant; Graft Versus Host Disease (GVHD)
Children's Hospital Medical Center, Cincinnati
 2014-07 PHASE1; PHASE2
NCT03708861 WITHDRAWN
HIV Infection
University of Turin, Italy
 2016-01 PHASE3
NCT02208037 COMPLETED
Acute Leukemia; Chronic Myelogenous Leukemia; Myelodysplasia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Hodgkin's Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)
 2014-08 PHASE2
NCT02881762 Completed
Hepatitis C|Human Immunodeficiency Virus
University of Maryland Baltimore|ViiV Healthcare
 2017-06-01 Phase 4
NCT02778204 Completed
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|ViiV Healthcare|GlaxoSmithKline
 2017-06-05 Phase 1
NCT03402815 COMPLETED
HIV Infection With Other Conditions; Cardiovascular Risk Factor; Atherosclerosis; Inflammation
University Of Perugia
 2015-01-01 PHASE4
NCT02741323 Completed
HIV Infections|Kidney Diseases
National Institute of Allergy and Infectious Diseases (NIAID)
 2017-01-01 Phase 2
NCT02799888 UNKNOWN
Graft-versus-host Disease; Hematopoietic Stem Cell Transplantation
Affiliated Hospital to Academy of Military Medical Sciences
 2014-04 PHASE2
NCT01785810 COMPLETED
Hematologic Malignancy
Abramson Cancer Center at Penn Medicine
 2013-02 PHASE2
NCT03178084 COMPLETED
HIV/AIDS
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
 2014-10-15 PHASE3
NCT02333045 TERMINATED
HIV
Emory University
 2015-01
NCT02625207 COMPLETED
Healthy Subjects
ViiV Healthcare
 2015-11-06 PHASE1
NCT01348308 COMPLETED
HIV-1 Infection; AIDS
ANRS, Emerging Infectious Diseases
 2011-09 PHASE3
NCT01637259 COMPLETED
Proteinuria; HIV
Kirby Institute
 2012-06 PHASE4
NCT02486510 TERMINATED
HIV-1 Infection
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
 2012-07 EARLY_PHASE1
NCT01291459 UNKNOWN
HIV
Association Pour la Recherche en Infectiologie
 2011-09 PHASE2
NCT01384682 COMPLETED
HIV
Kirby Institute
 2011-08 PHASE4
NCT02346084 COMPLETED
HIV/AIDS
International Partnership for Microbicides, Inc.
 2015-01 PHASE1
NCT01680536 COMPLETED
HIV
St Stephens Aids Trust
 2012-11 PHASE4
NCT02475915 COMPLETED
Acute HIV Infection
SEARCH Research Foundation
 2015-01 PHASE1; PHASE2
NCT01505114 COMPLETED
HIV Infection
National Institute of Allergy and Infectious Diseases (NIAID)
 2012-06 PHASE2
NCT01367236 COMPLETED
HIV; Impaired Cognition
Imperial College London
 2013-01 PHASE4
NCT02480894 COMPLETED
Infection, Human Immunodeficiency Virus
ViiV Healthcare
 2015-07-07 PHASE1
NCT01367210 TERMINATED
HIV Infection
Catholic University of the Sacred Heart
 2011-06 PHASE4
NCT01749566 COMPLETED
HIV
Emory University
 2012-12 PHASE1
NCT02134717 TERMINATED
Sarcoidosis
Kevin F. Gibson
 2014-01
NCT00981318 TERMINATED
HIV Infections; Acquired Immunodeficiency Syndrome
Rodwick, Barry M., M.D.
 2009-12 PHASE4
NCT00791700 UNKNOWN
Human Immunodeficiency Virus
ViiV Healthcare
 2009-04-22 PHASE2
NCT01276236 COMPLETED
Kaposi's Sarcoma
University of California, San Francisco
 2011-03-09 PHASE2
NCT00795444 COMPLETED
HIV-1
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
 2008-03 PHASE2
NCT02934022 COMPLETED
HIV Infection
Southern California Institute for Research and Education
 2012-06
NCT01389063 UNKNOWN
Endothelial Dysfunction
S.F.L. van Lelyveld
 2012-01 PHASE4
NCT01449006 COMPLETED
Human Immunodeficiency Virus (HIV); HIV Associated Neurocognitive Disorders (HAND)
Bruce Brew
 2011-10 PHASE4
NCT01154673 COMPLETED
Acute HIV Infection
University of Toronto
 2011-11 PHASE2; PHASE3
NCT01400412 COMPLETED
HIV-1 Infection
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2012-01-17 PHASE2
NCT01533272 COMPLETED
HIV Infection
Hospital Clinic of Barcelona
 2012-02 PHASE4
NCT01204905 COMPLETED
HIV Infections
University of Maryland, Baltimore
 2010-09
NCT01719627 COMPLETED
HIV
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
 2012-10 PHASE1
NCT02039323 COMPLETED
Healthy Adult Females
University of North Carolina, Chapel Hill
 2014-02 PHASE1
NCT01980329 COMPLETED
Cytochrome P450 CYP3A5 Enzyme Polymorphism; Healthy Subjects; Pharmacokinetics of Maraviroc
Johns Hopkins University
 2013-01 PHASE1
NCT00525733 COMPLETED
HIV Infections
Rockefeller University
 2007-10
NCT01894776 COMPLETED
HIV Infection; HIV-1 Infection; Mycobacterium Avium Complex (MAC)
Ottawa Hospital Research Institute
 2013-06 PHASE1
NCT01866267 COMPLETED
Human Immunodeficiency Virus; AIDS
St. Hope Foundation
 2013-01 PHASE4
NCT01330199 COMPLETED
Healthy Adult Females
University of North Carolina, Chapel Hill
 2012-02 PHASE1
NCT01345630 TERMINATED
HIV-1
ViiV Healthcare
 2011-09 PHASE3
NCT01033760 COMPLETED
HIV-1 Infections
ANRS, Emerging Infectious Diseases
 2010-04 PHASE3
NCT00976404 COMPLETED
HIV Infection
Robert L. Murphy
 2009-11 PHASE2
NCT01327547 COMPLETED
HIV Coinfection
ViiV Healthcare
 2011-05-18 PHASE4
NCT01627717 COMPLETED
Healthy
Centre hospitalier de l'Université de Montréal (CHUM)
 2012-06 PHASE1
NCT00870363 COMPLETED
HIV Infections
University of California, Davis
 2009-04 PHASE4
NCT00993148 COMPLETED
HIV-1 Infection; HIV Infections
Northwestern University
 2010-05 PHASE2
NCT01420523 TERMINATED
Human Immunodeficiency Virus; Lipohypertrophy
ANRS, Emerging Infectious Diseases
 2011-12 PHASE2
NCT00981773 TERMINATED
HIV Infections
Imperial College London
 2009-09 PHASE4
NCT00988780 UNKNOWN
Immune Reconstitution Inflammatory Syndrome; HIV; HIV Infections
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
 2009-12
NCT00844519 COMPLETED
HIV Infection; Cardiovascular Disease; Inflammation; HIV Infections
University of California, San Francisco
 2010-01 PHASE3
NCT00987948 COMPLETED
HIV Infections
University of Hawaii
 2010-01 PHASE2
NCT01275625 COMPLETED
HIV
ViiV Healthcare
 2011-06 PHASE4
NCT01363037 COMPLETED
HIV Infections
International Partnership for Microbicides, Inc.
 2011-11 PHASE1
NCT01133210 COMPLETED
Hypertriglyceridemia
Washington University School of Medicine
 2011-01 PHASE1
NCT01597895 COMPLETED
Healthy
ViiV Healthcare
 2012-07 PHASE1
NCT00925756 COMPLETED
HIV Infections
University of California, San Diego
 2008-10-20 PHASE4
NCT00966329 COMPLETED
HIV; HIV Infections
Germans Trias i Pujol Hospital
 2009-10 PHASE4
NCT00537394 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2008-01 PHASE3
NCT01190293 COMPLETED
HIV Infection
St Stephens Aids Trust
 2010-01 PHASE4
NCT01348763 COMPLETED
HIV
Imperial College London
 2011-10 PHASE1
NCT01597648 COMPLETED
Infection, Human Immunodeficiency Virus I
GlaxoSmithKline
 2011-11 PHASE1
NCT01060618 COMPLETED
HIV Infections
Asociacion para el Estudio de las Enfermedades Infecciosas
 2009-05 PHASE2; PHASE3
NCT00875368 COMPLETED
HIV Infections
S.F.L. van Lelyveld
 2009-02 PHASE4
NCT00808002 COMPLETED
HIV Infections
Germans Trias i Pujol Hospital
 2009-02 PHASE3
NCT01242579 WITHDRAWN
HIV Infections
International Partnership for Microbicides, Inc.
 2011-01 PHASE1
NCT01290211 COMPLETED
Healthy
ViiV Healthcare
 2011-04 PHASE1
NCT01049204 TERMINATED
HIV Infections
St Stephens Aids Trust
 2009-07 PHASE4
NCT00703586 COMPLETED
HIV Infections
Rockefeller University
 2007-09 PHASE1
NCT00948753 COMPLETED
Graft-versus-host Disease; Hematopoietic Stem Cell Transplantation
Abramson Cancer Center at Penn Medicine
 2009-06 PHASE1; PHASE2
NCT00884858 COMPLETED
HIV Infections
ASST Fatebenefratelli Sacco
 2009-04 PHASE4
NCT01068873 TERMINATED
HIV Infections
Temple University
 2010-04 PHASE4
NCT01140412 TERMINATED
Healthy
ViiV Healthcare
 2010-07 PHASE1
NCT00478231 COMPLETED
Acquired Immunodeficiency Syndrome; HIV Infection
ViiV Healthcare
 2007-07 PHASE3
NCT00944541 COMPLETED
HIV Infection; HIV Infections
French National Agency for Research on AIDS and Viral Hepatitis
 2009-09 PHASE2
NCT00827112 COMPLETED
Human Immunodeficiency Virus-1
ViiV Healthcare
 2009-03 PHASE2
NCT00982878 COMPLETED
HIV Infections
Imperial College London
 2009-09 PHASE1
NCT00426660 COMPLETED
HIV Infections
ViiV Healthcare
 2007-02 PHASE3
NCT00719823 WITHDRAWN
Human Immunodeficiency Virus Type 1
ViiV Healthcare
 2008-08 PHASE3
NCT01056874 COMPLETED
Healthy; HIV Infections
ViiV Healthcare
 2010-03 PHASE1
NCT00735072 COMPLETED
HIV Infection
University of California, San Francisco
 2008-09 PHASE4
NCT00782301 WITHDRAWN
Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic
ViiV Healthcare
 2009-03 PHASE4
NCT00709111 COMPLETED
HIV Infections
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2009-01
NCT00783484 COMPLETED
Healthy Volunteers
Pfizer
 2008-10 PHASE1
NCT00775294 COMPLETED
HIV/AIDS
University of North Carolina, Chapel Hill
 2008-05 PHASE1
NCT00821535 COMPLETED
Human Immunodeficiency Virus (HIV) Infection
ViiV Healthcare
 2009-02 PHASE1
NCT00764465 COMPLETED
Healthy
Garden State Infectious Disease Associates, PA
 2008-10 PHASE2
NCT00717067 COMPLETED
Human Immunodeficiency Virus (HIV) Infection
ViiV Healthcare
 2008-07 PHASE4
NCT00771823 COMPLETED
HIV Infections
St Stephens Aids Trust
 2008-05 PHASE1
NCT00496782 TERMINATED
HIV Infections
ViiV Healthcare
 2007-07 PHASE1
NCT00427934 TERMINATED
Arthritis, Rheumatoid
Pfizer
 2007-02 PHASE2
NCT00853840 COMPLETED
AIDS
ViiV Healthcare
 2008-04 PHASE4
NCT00666705 COMPLETED
Healthy
ViiV Healthcare
 2008-02 PHASE4
NCT00098293 COMPLETED
HIV-1
ViiV Healthcare
 2004-11 PHASE3
NCT00098306 COMPLETED
HIV Infections
ViiV Healthcare
 2004-11 PHASE2; PHASE3
NCT00098722 COMPLETED
HIV Infections
ViiV Healthcare
 2004-12 PHASE2; PHASE3
NCT00098748 COMPLETED
HIV Infections
ViiV Healthcare
 2004-11 PHASE2; PHASE3
NCT00643643 COMPLETED
HIV Infections
ViiV Healthcare
 2002-10 PHASE2
NCT01235013 UNKNOWN
HIV-1 Infection
Hospital Clinic of Barcelona
 PHASE4
NCT00634959 COMPLETED
HIV
ViiV Healthcare
 2003-07 PHASE2
NCT01013987 UNKNOWN
HIV-1 Adults Patients; AIDS; Triple Class Failure
Fundación Huésped
 2010-02 PHASE4

(data from https://clinicaltrials.gov, updated on 2026-06-30)

Check the Maraviroc (UK-427857) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Maraviroc selectively binds to C-C chemokine receptor type 5 (CCR5), blocking the interaction of natural chemokine ligands such as MIP-1α, MIP-1β, and RANTES to prevent viral membrane fusion and entry into host immune cells. This targeted blockade of CCR5 signaling inhibits viral replication and attenuates neuroinflammatory pathways, underpinning its clinical application in treating HIV-1 infection and post-stroke cognitive impairment.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.